- About UsOur Story, Our Team & Support Information
- What We DoAdvocacy to Achieve the End of AIDS
- Accelerate Product Innovation & Availability
- Advance HIV/SRH Integration
- Advocate for Access to High-Impact Prevention
- Improve Research Conduct
- Promote Effective HIV Prevention Policy
- Strengthen Global Advocacy Networks
- Track and Translate the Field
- Our FocusInterventions to End the Epidemic
- ResourcesPublications, Infographics, Events & More
- MediaInformation & Resources for the Press
- Our BlogPrevention News & Perspective
October 12, 2017
Leading researcher Dr. Deborah Donnell tells us why the HIV Prevention Trials Network (HPTN) changed the design of one of two trials testing long-acting cabotegravir, as an injectable PrEP. Deb Donnell is an expert statistician, one of the great minds behind trial design and one of the best teachers we know.
Listen to the full podcast (11:56).
Highlights
- Key terms: Placebo-controlled, blinded, non-inferiority, superiority, double-dummy double-blind & open-label (2:18)
- Initial trial design for 083 vs 084: Why they started out so different (4:33)
- Finalized trial design for 083 & 084: The gold standard (1:57)
- The future of vaccine development and prevention research in the era of PrEP (1:38)
Additional Resources
- AVAC's Px Wire, Vol. 10, No. 2
- HPTN 083
- HPTN 084
- AVAC's Introduction to Long-Acting Injectables Infographic
Give this podcast a listen and tell us what you think!
More Px Pulse
For more episodes of Px Pulse, click here.